eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2016-06-25 13 2 687 692 10.13005/bbra/2085 14006 article Yousef Al-Saraireh 1 Futoon Alrawashdeh 2 Jehad Al-Shuneigat 3 Mohammed Alsbou 4 Nedal Alnawaiseh 5 Hani Al-Shagahin 6 Department of Pharmacology, Faculty of Medicine, Mutah University, Karak, Jordan. Post code. 61710. PO.Box: 7. Department of Anatomy and Histology, Faculty of Medicine, Mutah University, Karak, Jordan. Post code. 61710. PO.Box: 7. Department of Biochemistry and Molecular Biology, Faculty of Medicine, Mutah University, Karak, Jordan. Post code. 61710. PO.Box: 7. Department of Pharmacology, Faculty of Medicine, Mutah University, Karak, Jordan. Post code. 61710. PO.Box: 7. Department of Public Health, Faculty of Medicine, Mutah University, Karak, Jordan. Post code. 61710. PO.Box: 7. Department of Special Surgery, Faculty of Medicine, Mutah University, Karak, Jordan. Post code. 61710. PO.Box:7. Glypican-3 is a heparan sulfate proteoglycans (HSPGs) expressed at plasma membrane surface. Several studies demonstrated the re-expression of glypican-3 during the malignant transformation. Glypican-3 expression in hepatocellular carcinoma was suggested to be a diagnostic marker for differential diagnosis of hepatic nodules. The aim of the study is to evaluate the diagnostic value of glypican-3 as tumor marker not only in liver tumors but also in tumors of the other organs. A total of 95 surgically excised human tissues were subjected to immunohistochemical staining using a monoclonal antibody specific for glypican-3. These human tissues cover most of the common normal, benign, malignant and metastatic tumors originated from 27 anatomic sites. The immunohistochemical results revealed that glypican-3 was expressed in 21.7% of the normal tissues studied including stomach, small intestine, kidney (Normal cortex), and pancreas, while, the expression for glypican-3 was positive in 42.4% of the benign and malignant tumors. The most frequent expressing tumor was hepatocellular carcinoma. Moreover, for the first time, several tumor entities showed glypican-3 expression including malignant meningioma, Hodgkin’s lymphoma, B-non Hodgkin's lymphoma,T-non Hodgkin's lymphoma. https://www.biotech-asia.org/vol13no2/screening-of-glypican-3-expression-in-human-normal-versus-benign-and-malignant-tissues-a-comparative-study-glypican-3-expression-in-cancers/ Cancer; Glypican-3; Hepatocellular carcinoma; Immunohistochemistry; Proteoglycan